Abstract:In allogeneic hematopoietic stem cell transplantation recipients, cytomegalovirus (CMV) infection can cause overt CMV-associated disease, which is a main cause of transplantation-associated mortality. CMV infection correlates closely with donor's type. We therefore examined whether risk factors of CMV reactivation and clinical endpoints in patients with hematologic malignancies after allogeneic peripheral blood stem cell transplantation (PBSCT) differed between using matched-sibling donors (MSD-SCT) and haploidentical donors (HID-SCT). In this retrospective cohort study, we enrolled in 200 consecutive patients received an unmanipulated G-CSF-mobilized allogeneic PBSCT. Ninety (45%) patients received MSD-SCT and 110 (55%) received HID-SCT. Quantitative PCR was used for monitoring of CMV reactivation after transplantation. One-year cumulative incidence of CMV DNAemia was 55.0%, ranging from 23.5% in MSD-SCT group to 81.0% in HID-SCT group (p < 0.001). Although univariate analyses showed that non-myeloid malignancies, disease in complete remission status at transplantation, pretreatment with antithymocyte globulin, HLA-haploidentical donors, male donors, previous Epstein-Barr virus DNAemia, and absolute lymphocyte count on day 30 < 0.6 × 109/L were respectively associated with CMV reactivation after transplantation in total cohort of recipients (all p < 0.05), haploidentical donors were found to be the only independent predictor in multivariate analyses (Hazard ratio = 6.4, p < 0.001). Furthermore, univariate analyses revealed that non-myeloid malignancies and previous Epstein-Barr virus DNAemia were respectively associated with CMV reactivation in MSD-SCT recipients, and female was associated with CMV reactivation in HID-SCT recipients (all p < 0.05). In HID-SCT recipients, but not MSD-SCT recipients, previous CMV DNAemia was associated with a lower cumulative incidence of acute graft-versus-host disease (49.2% vs. 72.6%, p < 0.001). CMV DNAemia did not play a role in the relapse rate, but it was strongly associated with an increased risk of non-relapse mortality either in total cohort of recipients (30.5% vs. 13.7%; p = 0.003) or in the HID-SCT subgroup (36.0% vs. 16.7%; p = 0.030). Relapse-free survival and overall survival in total cohort of recipients with CMV DNAemia were both inferior to those without CMV DNAemia (45.3% vs. 57.6% and 54.8% vs. 65.8%, respectively; both p < 0.05). However, in subgroup analysis according to donor's type, neither relapse-free survival nor overall survival was impacted by CMV status (both p > 0.05). This study addressed differences in incidence, risk factors, and associations with clinical outcomes of CMV reactivation after haploidentical versus matched-sibling PBSCT.

Immune Reconstitution to Cytomegalovirus Following Partially Matched-Related Donor Transplantation: Impact of in Vivo T-cell Depletion and Granulocyte Colony-Stimulating Factor-Primed Peripheral Blood/bone Marrow Mixed Grafts.

Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8(+) T Cells Within Donor Grafts: Its Associations with Cytomegalovirus Reactivation Following Unmanipulated Allogeneic Hematopoietic Stem Cell Transplantation.

[Cytomegalovirus-Specific T Cells Immune Reconstitution after Human Leukocyte Antigen Matched Sibling Donor Allogeneic Bone Marrow Plus Peripheral Blood Hematopoietic Stem Cell Transplantation].

Cytomegalovirus-specific T cell immunity reconstitution following allogeneic hematopoietic stem cell transplantation: a pilot stduy

Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation

CMV Infection and CMV-Specific Immune Reconstitution Following Haploidentical Stem Cell Transplantation: An Update

Risk Factors and Associations with Clinical Outcomes of Cytomegalovirus Reactivation after Haploidentical Versus Matched-Sibling Unmanipulated PBSCT in Patients with Hematologic Malignancies.

Improving Cytomegalovirus-Specific T Cell Reconstitution after Haploidentical Stem Cell Transplantation.

The Potential Association of Delayed T Lymphocyte Reconstitution Within Six Months Post-Transplantation with the Risk of Cytomegalovirus Retinitis in Severe Aplastic Anemia Recipients.

Early Immune Surveillance to Predict Cytomegalovirus Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation.

Analysis of immune reconstitution and the incidence of cytomegalovirus infection after unrelated cord blood transplantation following myeloablative conditioning without antithymocyte globulin

CMV Infection Combined with Acute GVHD Associated with Poor CD8+ T-cell Immune Reconstitution and Poor Prognosis Post-Hla-matched Allo-Hsct

Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide

Lower Incidence of Cytomegalovirus Reactivation Following Post-Transplantation Cyclophosphamide HLA-Mismatched Unrelated Donor Transplantation

Distinct Activities of Vδ1+ T‐cells Upon Different Cytomegalovirus Reactivation Status after Haematopoietic Transplantation

Specific Immunity to Cytomegalovirus in Pediatric Cardiac Transplantation

Expansion of effector memory Vδ2neg γδ T cells associates with cytomegalovirus reactivation in allogeneic stem cell transplant recipients

Time-dependent Analysis of the Impact on Early Cytomegalovirus Reactivation of HLA Mismatch and Acute Graft-Versus-host Disease after Allogeneic Hematopoietic Cell Transplantation from Related Donors in Acquired Aplastic Anemia

Dynamics of cytomegalovirus‐specific T‐cell recovery in allogeneic hematopoietic cell transplant recipients using a commercially available flow cytometry assay: A pilot study

Cytomegalovirus Infection is Associated with Rapid NK Differentiation and Reduced Incidence of Relapse in HLA Matched Sibling Donor Transplant Patients.

Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation